The History of NARCAN® (naloxone HCl) Nasal Spray 4mg

NARCAN® Nasal Spray is the first and only FDA-approved naloxone nasal spray developed for use in a community setting. It was commercialized by ADAPT Pharma®, a privately-held pharmaceutical company, committed to positively impacting the lives of patients. The timeline below illustrates the commercialization process of NARCAN® Nasal Spray from product development through community deployment.

- **2013 September**: Product Development initiated in collaboration with the National Institute on Drug Abuse (NIDA).
- **2014**: Pharmacokinetic Study of drug absorption, distribution, metabolism, and excretion was conducted.
- **2015 February**: Licensing Agreement with Lightlake Therapeutics (now Opiant) for global rights to develop and commercialize a naloxone nasal spray.
- **2015 March**: NARCAN® brand name acquired.
- **2015 May**: Human Factor Study and label comprehension study initiated to assess the device’s ease-of-use.
- **2015 July**: Rolling Submission of new drug application (NDA) to the Food and Drug Administration (FDA) for priority review.
- **2016 February**: FDA Approves NARCAN® Nasal Spray 4mg, developed for community use.
- **2017 October**: Canada Interim Order and rapid implementation of an appropriate process to deliver and distribute NARCAN® Nasal Spray.